Results: Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer

Posted by Weill Cornell Breast Center in breast cancer, Breast Cancer News, Breast Cancer Prevention, breast cancer subtypes, Clinical Trials, Research Publications, Triple Negative Breast Cancer, Uncategorized and tagged with , , , , ,

Dr. Linda Vahdat and her colleagues are very excited to be involved in the development of glembatumuma vedotin as it has the potential to be among the very first drugs for triple negative breast cancer.

http://jco.ascopubs.org/content/early/2014/09/29/JCO.2013.52.5683.full.pdf+html

Leave a Comment

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Google photo

You are commenting using your Google account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s